# ESCALADE (NCT04529772)

> A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04529772
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Acerta Pharma BV
- Conditions: Diffuse Large B-Cell Lymphoma
- Interventions: acalabrutinib; placebo; Prednisone; Rituximab; Cyclophosphamide; Vincristine; Doxorubicin
- Enrollment: 611
- Primary outcome: Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 21
- Podcasts: 9
- X threads: 8

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=escalade-nct04529772

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04529772", "email": "<work email>"}; the inbox owner confirms by the emailed link.